Cancers, Vol. 15, Pages 1664: Mast Cell Leukemia: An Update with a Practical Review

Cancers, Vol. 15, Pages 1664: Mast Cell Leukemia: An Update with a Practical Review

Cancers doi: 10.3390/cancers15061664

Authors: Magda Zanelli Martina Quintini Salvatore Magnasco Lara Aprile Andrea Palicelli Maurizio Zizzo Francesca Sanguedolce Stefano Ricci Saverio Pancetti Valeria Zuccalà Veronica Martino Giuseppe Broggi Rosario Caltabiano Alberto Cavazza Paola Parente Cristina Mecucci Giovanni Martino Stefano Ascani

Mast cell leukemia (MCL) is the leukemic form of SM with at least 20% mostly immature mast cells on bone marrow aspirate. MCL may develop de novo, in the absence of a prior SM, or it may represent a progression from a previous SM. MCL may be sub-divided into the more frequent, aggressive acute form with signs of organ damage (C-findings) and the chronic form lacking C-findings and presenting a more stable course, although over time, progression to acute MCL is common. The 2022 WHO subtype of MCL with an associated hematological neoplasm was renamed MCL with an associated myeloid neoplasm in the 2022 International Consensus Classification (ICC). The relevance of the distinction between the leukemic and aleukemic forms based on the percentage of circulating mast cells is a matter of debate. The current knowledge on MCL is restricted mainly to single reports or case series with a limited number of larger studies. Our aim is to provide a comprehensive overview of this rare disease in terms of clinical manifestations, morphology, phenotype, molecular characteristics, differential diagnosis, outcome and treatment. A general overview on mastocytosis is also included.